Skip to content

Inspection Record

Immunomedics, Inc. — FDA 483 Findings

US FDAInspected 2018-08-01Published 2019-04-30 4 findingsOther quality systemData integrityLabeling and packaging

Inspectors Peter R LenahanThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

Not all participating investigators were informed of new observations discovered by or reported to the sponsor.

2Data integrity

Electronic records are used, but they do not meet systems validation and audit trail requirements to ensure that they are trustworthy, reliable and generally equivalent to paper records.

3Other quality system

Failure to ensure proper monitoring ofthe study and ensure the study is conducted in accordance with the protocol and/or investigational plan.

4Labeling and packaging

The immediate package of the investigational new drug does not bear a label with the statement "Caution: New Drug- Limited by Federal (or United States) law to investigational use

A record as of the US FDA document published on 2019-04-30. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Immunomedics, Inc. findings history — including this company's other documentsAll US FDA findings US FDA documents, 2019 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.